Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07344948 · ClinicalTrials.gov registry record · Early Phase 1
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
A Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis, sponsored by Neurosterix.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT07344948 is a Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis that is actively recruiting participants, run by Neurosterix. The registered enrollment target is 73 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07344948, a Early Phase 1 study of Healthy Participants and Schizophrenia Diagnosis, is actively recruiting participants, sponsored by Neurosterix.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NTX-253
Study Locations (1)
California
- Collaborative Neuroscience Research, LLC - CenExel - Los Alamitos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07344948
The ClinicalTrials.gov registry entry for NCT07344948 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (12% higher). The listed sponsor is Neurosterix, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07344948 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07344948 about?
NCT07344948 is a clinical study titled "Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia". This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
What is the current status of trial NCT07344948?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 73 participants. The study started on 2025-10-03. Estimated completion is 2026-05.
What conditions does trial NCT07344948 study?
This clinical trial studies the following conditions: Healthy Participants, Schizophrenia Diagnosis.
What interventions are being tested in trial NCT07344948?
The interventions under investigation include: Placebo (DRUG), NTX-253 (DRUG).
Who is sponsoring clinical trial NCT07344948?
This trial is sponsored by Neurosterix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07344948 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
Researching Economical Adjuvants to Cancer Therapy
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
Washington University WU 409: Immune Responses to Rabies Vaccine.
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.